This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Trinity Equity in Recapitalization of Ricerca Biosciences

March 9, 2010

NEW YORK, March 9, 2010 — Covington & Burling LLP represented Trinity Equity Investments I, LLC, an affiliate of Trinity Equity Investors, LLC, in its March 5 investment in, and recapitalization of, Ricerca Biosciences, LLC, which was completed in connection with Ricerca’s acquisition of the Discovery and Preclinical business of MDS Pharma Services. Covington has represented Trinity in all of its prior investments in Ricerca Biosciences dating back to 2000.

Ricerca Biosciences currently has capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up and IND-enabling toxicology. The addition of the MDS Pharma Services molecular profiling, pharmacology/DMPK and drug safety assessment services is expected to allow Ricerca to offer a more comprehensive suite of discovery and preclinical services to support drug candidates from discovery through IND on a global scale. Trinity Equity Investments invests primarily in leveraged buyout and growth equity investments in middle and lower middle market companies.

The Covington corporate team included partners Scott Smith, Peter Laveran and Rob Heller (tax), and associates Frank London and Rucia Pei (tax). All are based in New York with the exception of Mr. Laveran, who resides in the firm’s London office.

Share this article: